Ogden Christopher bought CTMX
January 18, 2024 · Form 4 insider transaction
Ogden Christopher bought 75,000 shares of CytomX Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
75,000
Price
$0.00
Total value
N/A
InsiderOgden Christopher
RoleOfficer
SecurityPerformance Stock Units (PSUs)
Transaction codeA: Grant or award
Transaction dateJanuary 18, 2024
Filing dateJanuary 19, 2024
Shares owned after75,000
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.